Should You Buy Oncothyreon Inc (ONTY) Ahead of Earnings? - Tale of the Tape
Investors are always looking for stocks that are poised to beat at earnings season and Oncothyreon Inc(ONTY) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.
That is because Oncothyreon Inc is seeing favourable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings-with the most up-to-date information possible-is a pretty good indicator of some favourable trends underneath the surface for ONTY in this report.
In fact, the Most Accurate Estimate for the current quarter is currently at a loss of 8 cents per share for ONTY, compared to a broader Zacks Consensus Estimate of a loss of 9 cents per share. This suggests that analysts have very recently bumped up their estimates for ONTY, giving the stock a Zacks Earnings ESP of 11.11% heading into earnings season.
Why is this Important?
A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises, and outperforming the market. Our recent 10 year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank #3 (Hold) or better show a positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns (see more Top Earnings ESP stocks here ).
Given that ONTY has a Zacks Rank #3 (Hold) and an ESP in positive territory, investors might want to consider this stock ahead of earnings. Clearly, recent earnings estimate revisions suggest that good things are ahead for Oncothyreon Inc, and that a beat might be in the cards for the upcoming report.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.